BioWorld

Jan. 9, 2002

DeCode Adding Chemistry Via $83.6M MediChem Acquisition

Calling the move not only logical, but necessary, DeCode Genetics Inc. said it is buying MediChem Life Sciences Inc. in a stock swap worth about $83.6 million. Read More

Pharmacyclics: Xcytrin Works In Lung-Brain Metastasis Group

Iowa University, IntronnJoin To Correct Cystic Fibrosis Mutant Gene In Customized Mouse Mimic

IDEC Hits Manufacturing Snag With Zevalin; Trials Not Needed

Other News To Note

Signature Adding To Oncology Portfolio Via PrimeCyte Purchase

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Maxygen Partners With Celltech To Work On Antibody Programs

3-D Pharma In-Licenses Drug From GSK Through Stock Deal

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...